EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

Rinvoq (upadacitinib) has been authorised by the EMA for multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Atopic Dermatitis
• Axial Spondyloarthritis
• Crohn Disease
• Giant Cell Arteritis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Psoriatic;Axial Spondyloarthritis;Spondylitis, Ankylosing;Giant Cell Arteritis;Dermatitis, Atopic;Colitis, Ulcerative;Crohn Disease. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 11/06/2026